logo

NNNN

Anbio Biotechnology·NASDAQ
--
--(--)
--
--(--)
6.92 / 10
Outperform

Financial analysis yields a solid fundamental rating of Outperform with a score of 6.9/10. The inventory turnover ratio of 38.0153 (Group 2) and fixed assets turnover ratio of 1032.3089 (Group 3) point to efficient asset utilization. A gross profit margin of 92.3235% underscores strong profitability. However, the current assets turnover ratio of 0.1984 (Group 2) is suboptimal, indicating potential inefficiencies in short-term asset management. Historical back-tests show mixed one-month returns (e.g., 5.89% for inventory, 1.53% for fixed assets), suggesting that while fundamentals are sound, they may not consistently outperform in the near term.

Fundamental(6.92)SentimentTechnical

Analysis Checks(3/4)

Inventory turnover ratio
Value38.02
Score3/3
Weight65.97%
1M Return5.89%
Gross profit margin (%)
Value92.32
Score2/3
Weight16.01%
1M Return1.40%
Current assets turnover ratio
Value0.20
Score1/3
Weight2.79%
1M Return0.27%
Fixed assets turnover ratio
Value1032.31
Score3/3
Weight15.23%
1M Return1.53%
Is NNNN undervalued or overvalued?
  • NNNN scores 6.92/10 on fundamentals and holds a Discounted valuation at present. Backed by its 16.98% ROE, 37.20% net margin, 1433.82 P/E ratio, 133.97 P/B ratio, and 100.92% earnings growth, these metrics solidify its Outperform investment rating.